Since May, Circumvent Pharma has been very busy working to create value for patients and investors. We iterated on our original commercialization and development plan, and we are outlining unique financing strategies for early stage development. We have continued to engage experts in the biotechnology industry and experienced entrepreneurs to receive feedback on the best path for us moving forward. We have also had interactions with angel investors and potential industry partners and received very useful feedback from them as well. We are continuing to develop relationships with scientific and medical key opinion leaders and patient organizations. We are also working to establish research and development collaborations that will be critical for the development of this technology. The CAI (Rosemarie, Youhong, and Jonathan) has provided a wealth of resources to us from day 1 of the competition to the start-up phase. We truly appreciate what they have done in providing this opportunity to us and helping us move this project forward. We hope to have additional updates soon toward our goal of delivering therapies for patients with very high unmet needs.